Trulieve Cannabis Corp. quarterly report, Q2 FY2026

Trulieve Cannabis Corp. 10-Q Summary: Q2 2026

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Trulieve Cannabis Corp. is a vertically integrated medical cannabis operator with over 200 dispensaries across Florida, Pennsylvania, West Virginia, and Georgia. The reporting period is significantly impacted by the Deconsolidation Transaction completed on June 3, 2026, wherein the company ceased to control its former subsidiary, Harvest Enterprises, LLC (holding mixed-use operations in Arizona, Connecticut, Maryland, and Ohio). Following this transaction, Trulieve operates exclusively in medical cannabis markets and accounts for its retained interest in Harvest under the equity method.

Key Financial Metrics

Metric (in thousands) Q2 2026 Q2 2025 YTD 2026 YTD 2025
Revenue $270,952 $302,086 $557,706 $599,846
Gross Profit $162,289 $182,926 $332,370 $366,145
Gross Margin 59.9% 60.6% 59.6% 61.0%
Net Loss (GAAP) $(406,062) $(16,111) $(403,779) $(49,870)
Adjusted EBITDA $97,996 $110,613 $198,418 $219,803
Cash and Equivalents $325,420 $255,535 (Dec '25) $325,420 $239,710 (Dec '24)
Operating Cash Flow (YTD) $108,847 $137,224 $108,847 $137,224
Total Debt (Notes Payable + Private Placement) $285,209 $227,580 (Dec '25) $285,209 $227,580 (Dec '24)

Note: Debt figures exclude lease liabilities. Total debt increased due to a new $60M private placement tranche in Q1 2026.

Material Changes vs. Prior Period

  • Deconsolidation Loss: The company recognized a non-cash loss on deconsolidation of $403.3 million in Q2 2026. This charge resulted from derecognizing Harvest's net assets and measuring the retained equity investment at fair value. This is the primary driver of the reported GAAP net loss.
  • Revenue Decline: Revenue decreased 10% QoQ and 7% YTD, primarily due to the reduced period of consolidated Harvest activity. Excluding the transaction impact, revenue was affected by pricing pressure in mature markets, partially offset by growth in Ohio and management services revenue from Harvest.
  • Tax Provision: The provision for income taxes decreased significantly (60% QoQ) to $22.0 million. This reflects the company's decision not to apply IRC Section 280E for the 2026 taxable year following the DOJ's rescheduling of medical marijuana to Schedule III in April 2026.
  • Equity Method Investment: Post-deconsolidation, Trulieve holds a non-voting, non-participating interest in Harvest valued at approximately $152.5 million, recorded as an equity method investment.

Guidance, Outlook, and Risks

  • Regulatory Outlook: Following the April 2026 rescheduling of medical marijuana to Schedule III, Trulieve has applied for DEA registration in Florida, Georgia, Pennsylvania, and West Virginia. The company believes its operations in these states are federally lawful while applications are reviewed.
  • Expansion: Trulieve received conditional approval for a dispensing license in Texas and is preparing production capacity for inspection. Georgia's medical program expanded on July 1, 2026, removing low-THC caps.
  • Share Repurchase: In June 2026, the Board authorized a $50 million share repurchase program (up to 8.5 million shares), expiring June 2027. No shares have been repurchased as of June 30, 2026.
  • Key Risks:
    • Tax Litigation: The IRS proposed assessments of taxes, interest, and penalties totaling approximately $38.1 million in penalties (not included in uncertain tax liabilities) for prior years. Trulieve is contesting these vigorously.
    • Harvest Valuation: The fair value of the retained equity investment in Harvest is subject to volatility and significant management assumptions.
    • Competition: Intense competition in regulated markets and potential entry of better-capitalized competitors.

Investor Verification Checklist

  • Deconsolidation Accounting: Verify the $403.3 million loss is non-cash and understand the fair value methodology used for the retained Harvest investment ($152.5 million).
  • Tax Position: Confirm the status of the IRS audit protests and the specific impact of the Schedule III rescheduling on future tax liabilities and the $598.2 million uncertain tax position liability.
  • Liquidity: Assess the sufficiency of the $325.4 million cash balance against upcoming debt maturities (notably $200M private placement notes due in 2030) and capital expenditure needs.
  • Harvest Relationship: Review the Management Services Agreement (MSA) terms, specifically the 5% margin and fixed fees, to understand ongoing revenue streams from the deconsolidated entity.
  • Share Repurchase Execution: Monitor the execution of the newly authorized $50 million buyback program for potential impact on share count and liquidity.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.